Direct Endoscopic Necrosectomy Significantly Improves Treatment Success in Infected Necrotizing Pancreatitis

Article

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session when compared with patients who received the step-up treatment approach.

Direct endoscopic necrosectomy at index session, as opposed to the step-up approach, for patients with infected necrotizing pancreatitis significantly reduced the number of reinterventions to obtain treatment success as well as decreased the length of hospital stay, according to data presented at Digestive Disease Week (DDW) 2023.1

Direct Endoscopic Necrosectomy Significantly Improves Treatment Success in Patients With Infected Necrotizing Pancreatitis

Ji Young Bang, MD

Credit: Orlando Health Digestive Health Institute Center

“Endoscopic treatment is the preferred approach for management of infected necrotizing pancreatitis,” wrote Ji Young Bang, MD, Orlando Health Digestive Health Institute Center, and colleagues. “While transluminal stent placement followed by performance of direct endoscopic necrosectomy when there is no clinical improvement is a commonly practiced interventional strategy, the optimal timing to perform endoscopic debridement is unclear.”

In a multicenter, randomized trial, investigators compared outcomes between direct endoscopic necrosectomy and index session and compared it with the step-up approach for patients with infected necrotizing pancreatitis. A total of 70 patients with either confirmed or suspected infected necrotizing pancreatitis who needed intervention between November 2019 and October 2022 were included.

Patients were assigned to groups that either received direct endoscopic necrosectomy at index treatment session after lumen-apposing metal stent placement (n = 37) or received a step-up approach, in which necrosectomy was only conducted if no clinical improvement after stent placement was observed (n = 33). The primary endpoint was the number of reinterventions performed to obtain treatment success, which defined as symptom relief in combination with disease resolution on computed tomography at the 6-month mark.

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session (0.9) when compared with patients who received the step-up treatment approach (2.5; P = .001).

Although the overall hospital length stay was significantly shorter in the cohort of patients receiving the direct endoscopic necrosectomy (median 9 days [interquartile range (IQR) 7-20] vs 19 days [IQR 9-33], P = .048), no significant differences in treatment success (94.6% vs 90.9%, P = .66), adverse events (45.9% vs 60.6%, P = .22), mortality (0% vs 6.1%, P = .22), and the mean number of readmissions (.8% vs .8, P = .93) were observed between the direct endoscopic necrosectomy group and step-up treatment group.

References

  1. Young Bang J, Lakhtakia S, Thakkar S, Buxbaum J, et al. DIRECT ENDOSCOPIC VERSUS STEP-UP TRANSLUMINAL INTERVENTIONS IN NECROTIZING PANCREATITIS (DESTIN): RESULTS OF A RANDOMIZED TRIAL. Abstract presented at Digestive Disease Week (DDW) 2023 Annual Meeting. Chicago, IL. May 6-10, 2023.
Recent Videos
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
1 KOL is featured in this Insights series.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.